Skip to main content
Equibles

SMSPHARMA · SMS Pharmaceuticals Limited · Financials

Use SMSPHARMA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SMSPHARMA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
508.70 INR -16.05 (-3.06%) At close · Nov 13
Rebalance outlook locked
Volume · Nov 13 15.38K Avg daily vol (3M) 38.31K

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
8.87B +13.3%
FY2026 Revenue FY2020–FY2026
Net Income
1.02B +48.8%
FY2026 Net Income FY2020–FY2026
Operating Cash Flow
592.24M -27.5%
FY2026 Operating Cash Flow FY2022–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item TTM FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
INR 9.71B 8.87B 7.83B 7.09B 5.22B 5.2B 5.63B 4.12B
INR 405.79M 399.19M 343.37M 315.16M 321.25M 321.53M 222.82M 220.66M
INR 227.34M 230.76M 185.41M 234.57M 219.15M 188.75M 111.63M 122.11M
INR — — — — — — — 507.56M
INR 343.26M 286.4M 249.39M 169.07M 14.65M 6.18M 301.55M 180.67M
INR 1.17B 1.02B 686.11M 0 0 622.2M 625.27M 0
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 145.51M in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.